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Don’t Hurt My Brain . . .
It’s My Second Favorite Organ*
Christopher J. White, MD
New Orleans, Louisiana
Like most interventional cardiologists, my favorite organ is
the heart, and my major interest is percutaneous coronary
revascularization. Early in my career, however, my partners
and I appreciated the significant overlap of peripheral
vascular disease in our coronary patients that was amenable
to percutaneous intervention. We undertook to gain the
skills necessary to extend our interventional practice beyond
the borders of the heart (1). This included acute stroke
intervention, which we performed with the support and
guidance of our neurology and neuroradiology colleagues
(2). Practicing in both domains has revealed a striking
disparity between the interventional cardiology community’s
crusade to achieve early reperfusion for heart attacks and the
neurointerventional community’s general lack of commit-
ment to urgent revascularization for stroke.
See page 386
The Patel and Saver (3) recent comparative analysis of
reperfusion therapy for stroke and heart attack confirms our
observations. Although a national heart attack quality ini-
tiative has enabled interventional cardiologists to achieve
dramatic reductions in door-to-balloon times (4), acute
stroke therapy languishes without a mandate to provide
early reperfusion. Amazingly, in 2013, door-to-balloon
times comparable to heart attacks are not the standard of
care for acute stroke therapy (3).
Acute ischemic strokes are referred to as “brain attacks” to
emphasize the need for urgent therapy to maximize func-
tional recovery. Reducing time to reperfusion, which is
critical to preserving functional brain, is a 2-part problem.
First is the time it takes the patient to acknowledge his
symptoms and get to a hospital (onset-to-door time). Second
is the time it takes the emergency department physician to
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The first part of the problem, the onset-to-door time, has
been addressed by patient education programs sponsored by
the American Stroke Association and American Heart
Association aimed at improving patients’ awareness of
stroke symptoms and the need to seek urgent medical
attention. The second part, the door-to-needle or door-to-
balloon time for stroke reperfusion, however, has posed a
significant challenge. Embarrassingly, in the United States,
the majority of ischemic stroke patients presenting for care
do not receive any form of reperfusion therapy (5–7).
Whereas rapid initiation of intravenous tissue-type plasmin-
ogen activator with a door-to-needle time of 60 min is
important for a good outcome, the American Heart Asso-
ciation GWTG-Stroke (Get With The Guidelines-Stroke)
national registry reported that fewer than one-third of
stroke patients treated with intravenous tissue-type plas-
minogen activator were treated in 60 min of arrival at the
hospital (8). The vast majority of U.S. hospitals have neither
the capacity to provide catheter-based stroke intervention,
nor the desire to transfer eligible patients for appropriate
care. Why is this the case for acute stroke therapy, but not
for heart attacks?
In this issue of JACC: Cardiovascular Interventions, Roth
et al. (9) describe a rapidly effective stroke reperfusion
technique using a new mechanical thrombectomy device
(Solitaire, FR., Covidien, Mansfield, Massachusetts) in
patients with occlusion of a large intracranial vessel present-
ing within 4.5 h of stroke onset. In this prospective trial, the
investigators achieved 1 of the highest reperfusion rates
(95%) reported for stroke thrombectomy, at a mean door-
to-device (D2D) time of 95 33 min, which is dramatically
better than has previously been reported and is consistent
with a recently published randomized trial demonstrating
superiority of the Solitaire, FR. device compared to a
conventional thrombectomy device (Merci Retriever, Con-
centric Medical, Mountain View, California) (10). This
self-expanding stentlike device offers improved deliverability
over conventional mechanical thrombectomy catheters,
which tend to be bulky and which can be difficult to
manipulate in the tortuous intracranial vessels that are
encased in skull bone. Almost two-thirds of treated patients
had a favorable clinical outcome (modified Rankin score
2) at 3 months, with a very low risk of intracranial
hemorrhage (2.5%) and an acceptable mortality (12.5%) in
this high-risk population.
This paper is an important contribution to the literature
for several reasons. Roth et al. (9) were able to achieve a very
high technical success rate with rapid D2D times and better
clinical outcomes in those with earlier reperfusion. The
excellent D2D time (95  33 min), with two-thirds of
atients treated within 100 min, is evidence of the clinical
nd organization skills of the investigators and their stroke
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393teams. Similar to heart attack therapy, patients who had
earlier reperfusion (D2D 100 min) were more likely to
have a favorable outcome (66% with modified Rankin score
2) than were those with D2D times 100 min with only
44% having modified Rankin score 2.
How will this affect the clinical treatment of stroke
patients who are candidates for interventional therapy? It
will encourage further development of new devices to
enhance and enable more rapid reperfusion for stroke
patients, and it will highlight the feasibility of stroke teams
achieving D2D times for stroke similar to those achieved by
coronary interventionalists for heart attacks. There are
manpower challenges in neuroradiology that preclude offer-
ing a 24-7-365, on-demand, stroke service in many cities
and regions (6). A major reason, if not the biggest reason,
for the lack of on-demand catheter-based stroke therapy is
the neuroradiology manpower shortage. Whereas there are
adequate numbers of neuroradiologists available to meet
clinical demands during regular working hours, there are far
too few to offer every night call coverage for acute stroke
therapy in their hospitals. There is, however, a large pool of
skilled interventional cardiologists who are currently offer-
ing on-demand catheter-based therapy for heart attacks and
who have achieved cervico-cerebral angiographic compe-
tence associated with carotid stent placement. Why not add
their manpower to the stroke team and allow them to
supplement the neuroradiologists?
Will there ever be a national quality mandate for on-
demand catheter-based access for stroke reperfusion ther-
apy? The current heart attack national quality mandate,
requiring public reporting of D2B by hospitals, has been a
dramatic success. Regrettably, turf wars between specialties
have interfered with delivering optimal care for stroke
patients. It is way past time for neurologists to recruit
carotid stent–capable interventional cardiologists to join
multispecialty stroke teams to improve a stroke patient’s
access to this important therapy (11). Our current health-
care paradigm emphasizes “patient centeredness.” What
could be more patient centered than offering on-demand
revascularization for acute stroke therapy? sReprint requests and correspondence: Dr. Christopher J. White,
System Chairman of Cardiovascular Disease, John Ochsner Heart
and Vascular Institute, Ochsner Clinic Foundation, New Orleans,
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